Hein J. Verberne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hein J. Verberne has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
G. Aernout Somsen
Cardiology Centres the Netherlands, Amsterdam, The Netherlands
12 shared publicationsBerthe L. F. van Eck-Smit
Department of Nuclear Medicine, F2-238, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
11 shared publicationsArnold F. Jacobson
GE Healthcare, Princeton, NJ, USA
4 shared publicationsDerk O. Verschure
Department of Radiology and Nuclear Medicine, F2-238, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
4 shared publications- Erik S. G. Stroes
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands (Weijs, Hovingh, Kees Hovingh, Reeskamp, Stroes, and Schonck)
4 shared publications - Berthe L. F. van Eck-Smit
Department of Radiology and Nuclear Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
18F-FDG-PET/CT Leads to Improved Source Control of Extracardiac Complications in Infective Endocarditis
Extra-cardiac complications (ECCs) contribute to morbidity and mortality in patients with infective endocarditis (IE). Current guidelines recommend 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a screening tool for ECCs. This study assessed the clinical impact of ECCs detected by 18F-FDG-PET/CT compared to conventional diagnostics in patients with suspected IE. Patients with possible or definite IE (ESC 2015 criteria) were prospectively enrolled in the Amsterdam UMC endocarditis team registry from October 2016 till March 2021. The primary outcome, the number of source control interventions (SCIs), was analyzed using Cox regression analyses extended for recurrent events, with 18F-FDG-PET/CT as a time-dependent covariate. Secondary outcomes included the crude number needed to scan to perform one additional SCI, predictors associated with SCIs, and 90-day all-cause mortality adjusted for both immortal time bias and confounders. We included 252 patients, 152 in the 18F-FDG-PET/CT group and 100 in the control group. In the control group, 18 SCIs were performed. In the 18F-FDG-PET/CT group, 57 SCIs were performed, of which 21 were prompted by 18F-FDG-PET/CT findings. The crude number needed to scan leading to one additional SCI was 8 (95% CI 6-15). 18F-FDG-PET/CT was associated with the number of SCIs, with an adjusted hazard ratio of 2.96 (95% CI 1.36-6.44). No variables were significantly associated with 18F-FDG-PET/CT-related SCI. No differences were found in mortality between the control and PET/CT group (HR 0.69, 95% CI 0.40-1.20). The use of 18F-FDG-PET/CT among patients with suspected IE leads to increased source control interventions for ECCs. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/18f-fdg-pet-ct-leads-to-improved-source-control-of-extra-cardiac-complications-in-infective-endocarditis-7a6f6a49-5d38-4334-915f-c0f79a91edf9?utm_campaign=tidbitlinkshare&utm_source=IO
- 18 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open Access18F-FDG-PET/CT Leads to Improved Source Control of Extracardiac Complications in Infective Endocarditis
Extra-cardiac complications (ECCs) contribute to morbidity and mortality in patients with infective endocarditis (IE). Current guidelines recommend 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a screening tool for ECCs. This study assessed the clinical impact of ECCs detected by 18F-FDG-PET/CT compared to conventional diagnostics in patients with suspected IE. Patients with possible or definite IE (ESC 2015 criteria) were prospectively enrolled in the Amsterdam UMC endocarditis team registry from October 2016 till March 2021. The primary outcome, the number of source control interventions (SCIs), was analyzed using Cox regression analyses extended for recurrent events, with 18F-FDG-PET/CT as a time-dependent covariate. Secondary outcomes included the crude number needed to scan to perform one additional SCI, predictors associated with SCIs, and 90-day all-cause mortality adjusted for both immortal time bias and confounders. We included 252 patients, 152 in the 18F-FDG-PET/CT group and 100 in the control group. In the control group, 18 SCIs were performed. In the 18F-FDG-PET/CT group, 57 SCIs were performed, of which 21 were prompted by 18F-FDG-PET/CT findings. The crude number needed to scan leading to one additional SCI was 8 (95% CI 6-15). 18F-FDG-PET/CT was associated with the number of SCIs, with an adjusted hazard ratio of 2.96 (95% CI 1.36-6.44). No variables were significantly associated with 18F-FDG-PET/CT-related SCI. No differences were found in mortality between the control and PET/CT group (HR 0.69, 95% CI 0.40-1.20). The use of 18F-FDG-PET/CT among patients with suspected IE leads to increased source control interventions for ECCs. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/18f-fdg-pet-ct-leads-to-improved-source-control-of-extra-cardiac-complications-in-infective-endocarditis-7a6f6a49-5d38-4334-915f-c0f79a91edf9?utm_campaign=tidbitlinkshare&utm_source=IO
- 6 June 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 48, 102232
The potential of myocardial sympathetic innervation reserve in heart failure
- 6 June 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 48, 102232
The potential of myocardial sympathetic innervation reserve in heart failure
- Open Access
- 7 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (3) , 444-460
Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection. Traditional biomarkers of inflammation, such as high-sensitivity C-reactive protein, show an association with cardiovascular risk on a population level but do not have specificity for local plaque inflammation. Nowadays, advancements in non-invasive imaging of the vasculature enable direct assessment of vascular inflammation. Positron emission tomography (PET) tracers such as 18F-fluorodeoxyglucose enable detection of metabolic activity of inflammatory cells but are limited by low specificity and myocardial spillover effects. 18F-sodium fluoride is a tracer that identifies active micro-calcification in plaques, indicating vulnerable plaques. Gallium-68 DOTATATE targets pro-inflammatory macrophages by binding to somatostatin receptors, which enhances specificity for plaque inflammation. Coronary computed tomography angiography (CCTA) provides high-resolution images of coronary arteries, identifying high-risk plaque features. Measuring pericoronary adipose tissue attenuation on CCTA represents a novel marker of vascular inflammation. This review examines both established and emerging methods for assessing atherosclerosis-related inflammation, emphasizing the role of advanced imaging in refining risk stratification and guiding personalized therapies. Integrating these imaging modalities with measurements of systemic and molecular biomarkers could shift atherosclerotic cardiovascular disease management towards a more personalized approach.
- 7 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (3) , 444-460
Open AccessEstimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection. Traditional biomarkers of inflammation, such as high-sensitivity C-reactive protein, show an association with cardiovascular risk on a population level but do not have specificity for local plaque inflammation. Nowadays, advancements in non-invasive imaging of the vasculature enable direct assessment of vascular inflammation. Positron emission tomography (PET) tracers such as 18F-fluorodeoxyglucose enable detection of metabolic activity of inflammatory cells but are limited by low specificity and myocardial spillover effects. 18F-sodium fluoride is a tracer that identifies active micro-calcification in plaques, indicating vulnerable plaques. Gallium-68 DOTATATE targets pro-inflammatory macrophages by binding to somatostatin receptors, which enhances specificity for plaque inflammation. Coronary computed tomography angiography (CCTA) provides high-resolution images of coronary arteries, identifying high-risk plaque features. Measuring pericoronary adipose tissue attenuation on CCTA represents a novel marker of vascular inflammation. This review examines both established and emerging methods for assessing atherosclerosis-related inflammation, emphasizing the role of advanced imaging in refining risk stratification and guiding personalized therapies. Integrating these imaging modalities with measurements of systemic and molecular biomarkers could shift atherosclerotic cardiovascular disease management towards a more personalized approach.
- 6 December 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 45, 102105
Washout rate of cardiac 123I-meta-iodobenzylguanidine and ischemic stroke outcome
- 6 December 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 45, 102105
Washout rate of cardiac 123I-meta-iodobenzylguanidine and ischemic stroke outcome
- Open Access
- 30 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (2) , ytae043
Severe silent ischaemia detected with an Apple Watch in the home setting: a case report
Background: The Apple Watch has the capability to record a lead 1 electrocardiogram (ECG) and can identify and report atrial fibrillation. The use for detecting myocardial ischaemia is not endorsed by Apple but is documented in this case. Case summary: A 76-year-old man made a lead 1 ECG with his Apple Watch immediately after exercising on a cross trainer. He was fully asymptomatic. The ECG showed an unusual negative T-wave in this lead 1 that deepened in a few minutes and returned to normal after 22 min. He consulted a cardiologist and a standard exercise ECG confirmed the negative T-wave in lead 1 after maximal exercise and in addition showed widespread ST-depression indicating myocardial ischaemia, again without any clinical symptoms. Further studies revealed severe obstructive three-vessel coronary artery disease that was considered not suitable for percutaneous intervention. A coronary artery bypass operation on all involved vessels was performed successfully. Recovery was uneventful and an exercise ECG repeated 11 weeks later was normal. Discussion: We demonstrated that the lead 1 ECG made with the Apple Watch can reliably record T-wave changes indicating myocardial ischaemia. The use of the Apple Watch to document ischaemic changes should be studied systematically for its potential to identify myocardial ischaemia, mainly triggered by symptoms but maybe for asymptomatic persons as well.
- 30 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (2) , ytae043
Open AccessSevere silent ischaemia detected with an Apple Watch in the home setting: a case report
Background: The Apple Watch has the capability to record a lead 1 electrocardiogram (ECG) and can identify and report atrial fibrillation. The use for detecting myocardial ischaemia is not endorsed by Apple but is documented in this case. Case summary: A 76-year-old man made a lead 1 ECG with his Apple Watch immediately after exercising on a cross trainer. He was fully asymptomatic. The ECG showed an unusual negative T-wave in this lead 1 that deepened in a few minutes and returned to normal after 22 min. He consulted a cardiologist and a standard exercise ECG confirmed the negative T-wave in lead 1 after maximal exercise and in addition showed widespread ST-depression indicating myocardial ischaemia, again without any clinical symptoms. Further studies revealed severe obstructive three-vessel coronary artery disease that was considered not suitable for percutaneous intervention. A coronary artery bypass operation on all involved vessels was performed successfully. Recovery was uneventful and an exercise ECG repeated 11 weeks later was normal. Discussion: We demonstrated that the lead 1 ECG made with the Apple Watch can reliably record T-wave changes indicating myocardial ischaemia. The use of the Apple Watch to document ischaemic changes should be studied systematically for its potential to identify myocardial ischaemia, mainly triggered by symptoms but maybe for asymptomatic persons as well.
- Open Access
- 22 September 2023
- Published by Springer Nature in EJNMMI Research
- Vol. 13 (1) , 1-4
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
- 22 September 2023
- Published by Springer Nature in EJNMMI Research
- Vol. 13 (1) , 1-4
Open AccessCYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
- Open Access
- 15 August 2023
- Published by Springer Nature in Diabetologia
- Vol. 66 (11) , 2164-2169
Atorvastatin lowers 68Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes
Aims/hypothesis: Inflammation is a core component of residual cardiovascular risk in type 2 diabetes. With new anti-inflammatory therapeutics entering the field, accurate markers to evaluate their effectiveness in reducing cardiovascular disease are paramount. Gallium-68-labelled DOTATATE (68Ga-DOTATATE) has recently been proposed as a more specific marker of arterial wall inflammation than 18F-fluorodeoxyglucose (18F-FDG). This study set out to investigate whether 68Ga-DOTATATE uptake is amenable to therapeutic intervention in individuals with type 2 diabetes. Methods: Individuals aged >50 years with type 2 diabetes underwent 68Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) at baseline and after 3 months treatment with atorvastatin 40 mg once daily. Primary outcome was the difference in coronary 68Ga-DOTATATE uptake, expressed as target-to-background ratio (TBR). The secondary outcome was difference in bone marrow and splenic uptake, expressed as the standardised uptake value (SUV). Results: Twenty-two individuals with type 2 diabetes (mean age 63.2±6.4 years, 82% male, LDL-cholesterol 3.42±0.81 mmol/l, HbA1c 55±12 mmol/mol [7.2%±3.2%]) completed both 68Ga-DOTATATE PET/CT scans. The maximum TBR was −31% (95% CI −50, −12) lower in the coronary arteries, and bone marrow and splenic 68Ga-DOTATATE uptake was also significantly lower post statin treatment, with a mean percentage reduction of −15% (95% CI −27, −4) and −17% (95% CI −32, −2), respectively. Conclusions/interpretation: 68Ga-DOTATATE uptake across the cardio–haematopoietic axis was lower after statin therapy in individuals with type 2 diabetes. Therefore, 68Ga-DOTATATE is promising as a metric for vascular and haematopoietic inflammation in intervention studies using anti-inflammatory therapeutics in individuals with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT05730634 Graphical
- 15 August 2023
- Published by Springer Nature in Diabetologia
- Vol. 66 (11) , 2164-2169
Open AccessAtorvastatin lowers 68Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes
Aims/hypothesis: Inflammation is a core component of residual cardiovascular risk in type 2 diabetes. With new anti-inflammatory therapeutics entering the field, accurate markers to evaluate their effectiveness in reducing cardiovascular disease are paramount. Gallium-68-labelled DOTATATE (68Ga-DOTATATE) has recently been proposed as a more specific marker of arterial wall inflammation than 18F-fluorodeoxyglucose (18F-FDG). This study set out to investigate whether 68Ga-DOTATATE uptake is amenable to therapeutic intervention in individuals with type 2 diabetes. Methods: Individuals aged >50 years with type 2 diabetes underwent 68Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) at baseline and after 3 months treatment with atorvastatin 40 mg once daily. Primary outcome was the difference in coronary 68Ga-DOTATATE uptake, expressed as target-to-background ratio (TBR). The secondary outcome was difference in bone marrow and splenic uptake, expressed as the standardised uptake value (SUV). Results: Twenty-two individuals with type 2 diabetes (mean age 63.2±6.4 years, 82% male, LDL-cholesterol 3.42±0.81 mmol/l, HbA1c 55±12 mmol/mol [7.2%±3.2%]) completed both 68Ga-DOTATATE PET/CT scans. The maximum TBR was −31% (95% CI −50, −12) lower in the coronary arteries, and bone marrow and splenic 68Ga-DOTATATE uptake was also significantly lower post statin treatment, with a mean percentage reduction of −15% (95% CI −27, −4) and −17% (95% CI −32, −2), respectively. Conclusions/interpretation: 68Ga-DOTATATE uptake across the cardio–haematopoietic axis was lower after statin therapy in individuals with type 2 diabetes. Therefore, 68Ga-DOTATATE is promising as a metric for vascular and haematopoietic inflammation in intervention studies using anti-inflammatory therapeutics in individuals with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT05730634 Graphical
- Open Access
- 18 May 2022
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 43 (8) , 877-880
Anatomical breast imaging-derived parameters do not provide incremental information in prediction of nonvisualization of sentinel lymph nodes on lymphoscintigraphy
Objective: Accurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN. The aim of this retrospective study was to investigate whether parameters derived from anatomical breast imaging can predict SLN nonvisualization on lymphoscintigraphy. Methods: For this retrospective study, all data of mammography, breast MRI, and lymphoscintigraphy of SLN procedures from January 2016 to April 2021 were collected and reviewed from the Amsterdam UMC database. Results: A total of 758 breast cancer patients were included in this study. SLN nonvisualization on planar lymphoscintigraphy at 2-h postinjection (pi) was 29.7% and was reduced after a second injection to 7.5% at late lymphoscintigraphy 4-h pi. Multivariable analysis showed that age ≥ 70 years (P = 0.019; OR, 1.82; 95% CI, 1.10–3.01), BMI ≥ 30 kg/m2 (P = 0.031; OR, 1.59; 95% CI, 1.04–2.43), and nonpalpable tumors (P = 0.034; OR, 1.54; 95% CI, 1.03–2.04) were independent predictors of SLN nonvisualization. Differences in tumor size, Breast Imaging-Reporting and Data System classification, or breast density were not significantly associated with SLN nonvisualization. Conclusion: This study shows that, by using a multivariable analysis, risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy at 2-h pi are age ≥ 70 years, BMI ≥ 30 kg/m2, and nonpalpable tumors. Parameters derived from mammography or breast MRI, however, are not useful to predict SLN nonvisualization on lymphoscintigraphy.
- 18 May 2022
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 43 (8) , 877-880
Open AccessAnatomical breast imaging-derived parameters do not provide incremental information in prediction of nonvisualization of sentinel lymph nodes on lymphoscintigraphy
Objective: Accurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN. The aim of this retrospective study was to investigate whether parameters derived from anatomical breast imaging can predict SLN nonvisualization on lymphoscintigraphy. Methods: For this retrospective study, all data of mammography, breast MRI, and lymphoscintigraphy of SLN procedures from January 2016 to April 2021 were collected and reviewed from the Amsterdam UMC database. Results: A total of 758 breast cancer patients were included in this study. SLN nonvisualization on planar lymphoscintigraphy at 2-h postinjection (pi) was 29.7% and was reduced after a second injection to 7.5% at late lymphoscintigraphy 4-h pi. Multivariable analysis showed that age ≥ 70 years (P = 0.019; OR, 1.82; 95% CI, 1.10–3.01), BMI ≥ 30 kg/m2 (P = 0.031; OR, 1.59; 95% CI, 1.04–2.43), and nonpalpable tumors (P = 0.034; OR, 1.54; 95% CI, 1.03–2.04) were independent predictors of SLN nonvisualization. Differences in tumor size, Breast Imaging-Reporting and Data System classification, or breast density were not significantly associated with SLN nonvisualization. Conclusion: This study shows that, by using a multivariable analysis, risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy at 2-h pi are age ≥ 70 years, BMI ≥ 30 kg/m2, and nonpalpable tumors. Parameters derived from mammography or breast MRI, however, are not useful to predict SLN nonvisualization on lymphoscintigraphy.
- 1 October 2020
- Published by European Association of Nuclear Medicine
Hybrid Imaging in conventional nuclear medicine
- 1 October 2020
- Published by European Association of Nuclear Medicine
Hybrid Imaging in conventional nuclear medicine
- Open Access
- 1 August 2019
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 26 (4) , 1188-1196
Role of cardiac 123I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD
- 1 August 2019
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 26 (4) , 1188-1196
Open AccessRole of cardiac 123I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD